Health Catalyst Inc Common Stock (HCAT)
Stock · NASDAQ · Technology
$1.73as of 10/16/2026
Price chart
Active signals
HCAT Signal Track Record
How signals performed across all stocks →What HCAT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -6.4% | 43% | September 8, 2026 |
| Bollinger Band Breakdown | 23 | -3.7% | 39% | August 7, 2026 |
| Bollinger Band Breakout | 16 | -5.0% | 25% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 13 | +0.5% | 54% | October 6, 2026 |
| Any 20-session window (baseline) | -3.3% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applicati…
- Sector
- Technology
- Industry
- Computer Software: Programming Data Processing
- Employees
- 1,200
- Website
- www.healthcatalyst.com/
Fundamentals
- 1-day range
- $1.74$1.81
- Market cap
- $170.70M
- P/E (trailing)
- —
- P/E (forward)
- 240.00
- EPS (trailing)
- $-3.68
- Dividend yield
- —
- Beta
- 1.51
- Avg. volume
- 631.8K
How Health Catalyst Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Health Catalyst Inc Common Stock Competitors
Chosen by industry and closest market cap.
- HCATHealth Catalyst Inc Common Stock$1.73▼ 4.17%Market cap $170.70MP/E —$0.955$3.62
- DOYUDouYu International Holdings Limited ADS$3.58▲ 0.00%Market cap $137.31MP/E 11.09$3.61$7.25
- SANGSangoma Technologies Corporation Common Shares$4.77▼ 0.21%Market cap $133.45MP/E —$4.71$7.62
- PODCPodcastOne Inc. Common Stock$1.75▼ 11.62%Market cap $99.95MP/E —$1.61$5.2
- GOAIEva Live Inc. Common Stock$1.55▼ 7.74%Market cap $69.48MP/E —$1.42$18
- TEADTeads Holding Co. Common Stock$0.401▼ 3.61%Market cap $67.51MP/E —$0.3922$1.82
- LGCLLucas GC Limited Ordinary Shares$1.64▼ 9.39%Market cap $56.48MP/E 0.51$1.75$545
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HCAT Health Catalyst Inc Common Stock | $170.70M | — | $1.73 | ▼ 4.17% | $0.955$3.62 |
| DOYU DouYu International Holdings Limited ADS | $137.31M | 11.09 | $3.58 | ▲ 0.00% | $3.61$7.25 |
| SANG Sangoma Technologies Corporation Common Shares | $133.45M | — | $4.77 | ▼ 0.21% | $4.71$7.62 |
| PODC PodcastOne Inc. Common Stock | $99.95M | — | $1.75 | ▼ 11.62% | $1.61$5.2 |
| GOAI Eva Live Inc. Common Stock | $69.48M | — | $1.55 | ▼ 7.74% | $1.42$18 |
| TEAD Teads Holding Co. Common Stock | $67.51M | — | $0.401 | ▼ 3.61% | $0.3922$1.82 |
| LGCL Lucas GC Limited Ordinary Shares | $56.48M | 0.51 | $1.64 | ▼ 9.39% | $1.75$545 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Health Catalyst (HCAT): Buy, Sell, or Hold Post Q2 Earnings?Yahoo · 9/30/2026
- 3 Software Stocks We’re Skeptical OfYahoo · 9/28/2026
- 3 Unprofitable Stocks That Fall ShortYahoo · 9/25/2026
- Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth RisksYahoo · 9/19/2026
- 3 Small-Cap Stocks We Steer Clear OfYahoo · 9/18/2026
- Population Health Management Market by Component, Functionality, End User, Organization Size - Global Forecast to 2031Yahoo · 9/18/2026
- Health Catalyst Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 9/18/2026
- Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/14/2026
Insider Activity
Insider Actions →- Tami Reller · October 1, 2026 · Grant128.9K
- Kohl Simeon · September 14, 2026 · Buy59.0K @ $1.79
- Kohl Simeon · September 14, 2026 · Grant2.75M
- Benjamin Albert · September 10, 2026 · Tax Withholding35.2K @ $1.67
- Benjamin Albert · September 1, 2026 · Tax Withholding321 @ $1.7
- Benjamin Landry · September 1, 2026 · Tax Withholding13.2K @ $1.7
- Jason Alger · September 1, 2026 · Tax Withholding18.0K @ $1.7
- Julie Larson-Green · September 1, 2026 · Grant9.8K
- Green Jill Hoggard · July 16, 2026 · Grant80.7K
- Julie Larson-Green · July 16, 2026 · Grant80.7K
- Justin Spencer · July 16, 2026 · Grant80.7K
- Steven H. Nelson · July 16, 2026 · Grant80.7K
- Benjamin Albert · June 10, 2026 · Tax Withholding34.5K @ $1.69
- Benjamin Albert · June 1, 2026 · Tax Withholding336 @ $1.37
- Benjamin Landry · June 1, 2026 · Tax Withholding13.8K @ $1.37
Institutional Ownership
March 31, 2026
- Total shares held
- 57.48M
- Total value held
- $72.41M
- Institutional holders
- 128
- Unknown12.88M
- Unknown6.31M
- Unknown5.78M
- Unknown5.14M
- Unknown2.90M
- Unknown2.89M
- Unknown2.75M
- Unknown2.47M
- Unknown1.88M
- Unknown1.50M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Health Catalyst Included in List of Unprofitable Stocks
Health Catalyst was recently named in a Yahoo Finance article listing unprofitable stocks that may fall short of expectations. The company currently trades near its support level, with an average analyst target of $1.77. This context highlights the ongoing focus on the company's profitability and valuation relative to its peers.
Health Catalyst Included in List of Unprofitable Stocks. Health Catalyst was recently named in a Yahoo Finance article listing unprofitable stocks that may fall short of expectations. The company currently trades near its support level, with an average analyst target of $1.77. This context highlights the ongoing focus on the company's profitability and valuation relative to its peers.